CCL2, CCL3, CCL4, CCL5; CXCL9, CXCL10, CXCL11; IL-7, IL-13, IL-15, IL-17; IFNα, IFNβ1; TNFα

Monoclonal antibodies will be made to:

Cell Surface Molecules:

CD45RO: commercial peptide used for fusion November 2008 (UMass Amherst); monoclonal antibodies (mAb) tested (BARC); no strong positives

IL-4Rα (CD124): equine IL-4-swine IL-4R recombinant protein expressed March 2008 (Cornell);hybridoma fusion completed May 2008 (Cornell); original mAb tested June (BARC); several strong positives; further testing November 2008 and more planned (BARC).

IL-13Rα (CD213A1): equine IL-4-swine IL-13R recombinant protein produced January 2009 (Cornell); mAb produced February 2009 (Cornell); original mAb tested February 2009 (BARC); questionable positives.

TCRβ: first hybridoma fusion completed May 2008 (Cornell); new equine IL-4-swine TCRβ recombinant protein production scheduled May 2009; new hybridoma fusion scheduled June 2009 (Cornell).

TCRα: first hybridoma fusion completed May 2008 (Cornell); new equine IL-4-swine TCRa recombinant protein production scheduled July 2009; new hybridoma fusion scheduled August 2009 (Cornell).

Cytokines and Chemokines:

CXCL10: protein production and purification completed May 2008 (Kingfisher); bioassay activity affirmed at (BARC) by October 2008; hybridoma  fusion completed December 2008 (UMass Amherst)

CXCL11: protein production and purification completed May 2008 (Kingfisher); bioassay activity affirmed at (BARC) by October 2008; hybridoma fusion completed December 2008 (UMass Amherst).

CCL2: protein production and purification completed November 2008 (Kingfisher); bioassay activity affirmed at (BARC) by March 2009; hybridoma fusion and mAb screening completed February 2009 (Cornell).

CCL5: protein production and purification completed February 2009 (Kingfisher); bioassay activity planned (BARC).

IFNβ: protein production and purification completed December 2008 (Kingfisher); positive bioassay activity (UMass Amherst); further testing planned (BARC).

IFNa: protein production completed December 2008 and purification in process (Kingfisher); no bioassay activity (UMass Amherst).

IL-13: protein production and purification completed in July and October 2008 (Kingfisher); bioassay activity testing (BARC) and retesting (Golde, PIADC) in process; hybridoma fusion February 2009 (Cornell).

IL-15: protein production and purification completed in January 2009 (Kingfisher); bioassay activity testing planned (BARC; Golde, PIADC).